Clinical Trial Update: Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of surufatinib combined with carboplatin/paclitaxel and with olaparib as first-line and maintenance therapy…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Olaparib (Olaparib)
• PACLITAXEL (PACLITAXEL)
• Surufatinib (Surufatinib)

Snippet

Sponsor: Anhui Provincial Cancer Hospital | Conditions: Ovarian Cancer | Phase 2 | Status: RECRUITING